Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
2023年5月18日 - 9:30PM
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced the departure of Neil Klompas, President and Chief
Operating Officer.
Mr. Klompas joined Zymeworks in 2007 as Chief Financial Officer
and served in multiple capacities until being named Chief Operating
Officer and President in 2022. At various points throughout his
tenure, he oversaw diverse areas within the Company including
finance, legal, business development, human resources, clinical
development, manufacturing, and other business functions, and
played a central role in building the Company’s programs and
leadership in novel multifunctional biotherapeutics during
Zymeworks’ formative years.
“I join our Board of Directors and other members of our
management team in thanking Neil for his many significant
contributions at Zymeworks. During his long tenure, he helped the
Company advance many enterprise developments, including multiple
financing and business development transactions as a private
company, which led to the Company’s initial public offering on the
New York Stock Exchange, multiple successful subsequent public
follow-on financing transactions, and the collaboration and
licensing agreement for zanidatamab with Jazz Pharmaceuticals,”
said Kenneth Galbraith, Chair and Chief Executive Officer of
Zymeworks. “Neil also provided invaluable support during my first
year as Chief Executive Officer, and I am very grateful for his
years of leadership and commitment to the Company. We wish Neil all
the best in his future endeavors.”
“I’m incredibly proud of what we have achieved and accomplished
at Zymeworks over the last sixteen years, and I want to express my
sincerest thanks and heartfelt appreciation to all of my current
and prior colleagues on the executive committee, Board of Directors
and across the entire organization for their contributions,
resilience, and dedication. While I am excited about the prospect
of stepping away from Zymeworks and exploring new opportunities,
I’m confident that the scientific, technical, and clinical
professionals at Zymeworks are among the most talented researchers
in their respective fields. Coupled with the Company’s strong focus
on innovation and technology, I am confident that the leadership
team will continue to make great progress in advancing the
Company’s emerging pipeline and making a meaningful difference in
the lives of patients who are impacted by difficult-to-treat
cancers,” added Mr. Klompas.
Mr. Klompas’ departure as the Company’s President and Chief
Operating Officer will be effective June 30, 2023, and he will
remain as an advisor to the Company to ensure a smooth
transition.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of
BeiGene and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking
Statements
This press release includes “forward-looking statements” or
information within the meaning of the applicable securities
legislation, including Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking statements in this press release
include, but are not limited to, statements that relate to
performance of management, the implementation of changes in
management and other information that is not historical
information. When used herein, words such as “plan”, “believe”,
“expect”, “may”, “continue”, “anticipate”, “potential”, “will”,
“progress”, and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation: clinical trials
may not demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; any of Zymeworks’ or its
partners’ product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; regulatory agencies may
impose additional requirements or delay the initiation of clinical
trials; the impact of new or changing laws and regulations; market
conditions; and the other risks described under “Risk Factors” in
Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended
March 31, 2023 (a copy of which may be obtained at www.sec.gov and
www.sedar.com). Although Zymeworks believes that such
forward-looking statements are reasonable, there can be no
assurance they will prove to be correct. Investors should not place
undue reliance on forward-looking statements. The above
assumptions, risks and uncertainties are not exhaustive.
Forward-looking statements are made as of the date hereof and,
except as may be required by law, Zymeworks undertakes no
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances, or to reflect the occurrences of unanticipated
events.
Contacts:
Investor Inquiries:Jack Spinks Director, Investor Relations(604)
678-1388ir@zymeworks.com
Media Inquiries:Diana PapoveDirector, Corporate
Communications(604) 678-1388media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 4 2024 まで 5 2024
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 5 2023 まで 5 2024